Dr Stuart Hogarth

Lecturer in Sociology of Science and Technology at Department of Sociology, University of Cambridge

Share

Dr Hogarth is Lecturer in Sociology of Science and Technology at the University of Cambridge.

Dr Hogarth's work focuses on biomedical innovation and his research has investigated a diverse range of emergent biotechnologies, such as stem cell therapies and synthetic biology. His primary interest is the impact of genomic science on the diagnostics sector, and he has published extensively on the political economy of diagnostic innovation, with a particular focus on regulatory governance and intellectual property rights.

Dr Hogarth uses an international comparative methodology to explore the
continued salience of national institutions such as regulatory regimes
and healthcare systems, in a bioeconomy which is increasingly
characterised by global governance structures, international scientific
collaborations and transnational flows of capital and scientific labour.

His work is situated at the interface of science and technology studies,
medical sociology, history of medicine, bioethics, innovation studies and
regulatory studies and involves interdisciplinary collaboration with
scholars across the domains of biomedicine, law, politics and public
health. He has long-standing collaborative links with Dr Kathy Liddell,
Director of the Centre for Law, Medicine and Life Sciences at Faculty of
Law Cambridge.

His work combines empirical research with normative analysis of public
policy and commercial strategy. He has produced policy reports for the
European Commission and Health Canada, and in the UK Human Genetics
Commission. He was a member of the Department of Health's Emerging
Science and Bioethics Advisory Committee from 2012-14, and currently
serves on an external strategy group advising the Medicines and
Healthcare Products Regulatory Agency's on the revision of the EU
regulations for diagnostic devices.

  • 26 January 2017, 4pm

    How to measure what can’t easily be measured

    The NIHR is working to shorten the time taken to develop drugs and other therapies, with the aim of reducing the length of the average process by 20 months. As part of this Push the Pace programme, NOCRI is aiming to develop a method for measuring the impact of the time reduction.

  • 6 September 2016

    The Future of Genomic Medicine Patents in Europe and the US

    This workshop will bring together academic and industry experts with relevant policy makers to discuss and analyse recent legal decisions in the US and Europe, and their implications for the future of precision medicine.